Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates that KW2449 ameliorates collagen-induced arthritis by blocking RIPK1-dependent necroptosis, highlighting its therapeutic potential for rheumatoid arthritis.
These findings suggest that the overexpression of RIPK1 is positively correlated with the severity of RA. KW2449, as a small molecule inhibitor targeting RIPK1, has the potential to be a therapeutic strategy for RA treatment by inhibiting RIPK1-dependent necroptosis.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: